Combining radiation with an immune system-boosting therapy called ipilimumab led to regression of metastatic tumors not targeted by the radiation in lung cancer patients, according to results of an early clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Patient characteristics measured at the index date included age, sex and ART classes received (ie, nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside/nucleotide reverse transcriptase inhibitors, PIs, ritonavir boosting therapy or other therapies).
75 patients (89%) received the whole RT dose as planned (50.4 Gy), 9 patients (11%) received more than 50.4 Gy because of concurrent boost radiation therapy to positive pelvic lymph node region (60Gy).
Nancy Crum-Cianflonetet al. [ 20] evaluated the impact of tenofovir and a boosted PI on renal dysfunction among 150 HIV-infected Caucasian patients Initiating both tenofovir and boosted PI therapy greatly impacted kidney function: 78 (52%) of subjects showed a reduction in eGFR, the median change being −12.1 ml/min/1.73m [95% confidence interval (CI), -9.1 to −14.1 ml/min/1.73m].
John, L. B., Kershaw, M. H. & Darcy, P. K. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.
Applications covered include using smart RT biomaterials for boosting cancer therapy with minimal side effects, combining RT with immunotherapy or chemotherapy, reducing treatment time or health care costs, and other incipient applications.
While treatment with unboosted protease inhibitors (PI) requires near perfect adherence for virologic suppression[1], the introduction of more potent non-nucleoside reverse transcriptase inhibitors (NNRTI) and ritonavir boosted PI therapy has lead to reliable virologic suppression at moderate levels of adherence for most, but not all patients[6] [9].
Based on the positive clinical data generated by AveXis from a small clinical trial in children, Novartis acquired AveXis for $8.7 billion to boost its gene therapy portfolio.
In patients, who did not receive an anticipated IOERT boost, postoperative radiation therapy included an external beam boost to the surgical bed with a margin of 1 2 cm in all directions to a total dose of ≥ 60 Gy.
The location of the tumor in the breast, the size of the breast, a left- versus right-sided lesion, a radiation therapy boost, and BMI are sometimes referred to as factors influencing the amount of radiation to the axilla.
Fisher's exact test was used to analyze if the location of the tumor in the breast, the size of the breast, or a left- versus right-sided lesion were predictors for not receiving an elective radiation dose at the SLN site, and binary logistic regression for body mass index (BMI), radiation therapy boost, and a tumor located in the laterocranial quadrant.
